- Home
- ETNB
ETNB
89bio Inc.
as 07-26-2024 4:00pm EST
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 849.1M | IPO Year: | 2019 |
| Target Price: | $26.67 | AVG Volume (30 days): | 989.9K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.58 - $18.30 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 133.30% |
Stock Insider Trading Activity of 89bio Inc. (ETNB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PALEKAR ROHAN | ETNB | Chief Executive Officer | Apr 1 '24 | Sell | $10.91 | 52,718 | $575,153.38 | 459,171 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | ETNB | Director10% Owner | Mar 4 '24 | Buy | $15.35 | 1,350,000 | $20,722,500.00 | 12,431,584 | SEC Form 4 |
| PALEKAR ROHAN | ETNB | Chief Executive Officer | Feb 26 '24 | Sell | $10.76 | 4,477 | $48,172.52 | 486,889 | SEC Form 4 |
| PALEKAR ROHAN | ETNB | Chief Executive Officer | Dec 29 '23 | Sell | $11.20 | 50,000 | $560,000.00 | 301,225 | SEC Form 4 |
Latest 89bio Inc. News
ETNB Breaking Stock News: Dive into ETNB Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
GlobeNewswire
2 months ago
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
GlobeNewswire
3 months ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
3 months ago
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
GlobeNewswire
3 months ago
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
TipRanks
3 months ago
‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
Compare ETNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETNB 89bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.